We came across a bullish thesis on Genmab A/S on Gabriel Koh’s Substack. In this article, we will summarize the bulls’ thesis on GMAB. Genmab A/S's share was trading at $33.87 as of January 13th. GMAB’s trailing and forward P/E were 14.83 and 12.58, respectively according to Yahoo Finance.
[caption id="attachment_1617126" align="aligncenter" width="768"]Genmab is a leading biotechnology company focused on antibody therapeutics for cancer and serious diseases, operating a royalty driven, asset light business model that...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.